Kumar Shria, Metz David C, Ginsberg Gregory G, Kaplan David E, Goldberg David S
Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Division of Gastroenterology, Veterans Health Administration, Philadelphia, PA, USA.
Aliment Pharmacol Ther. 2020 Apr;51(8):781-788. doi: 10.1111/apt.15677. Epub 2020 Mar 4.
Helicobacter pylori infection is the most important risk factor for non-proximal gastric adenocarcinoma, yet some posit it is protective against oesophageal adenocarcinoma and proximal gastric cancers.
To evaluate the incidence of and risk factors for future oesophageal and proximal gastric cancers, utilizing the largest North American cohort of patients with previously identified H pylori. Also to identify whether treatment and eradication of H pylori alter future oesophageal and proximal gastric cancer risk.
Retrospective cohort study within the Veterans Administration of 36 803 patients (median age 60.4 years; 91.8% male) with confirmed H pylori between 01 January 1994 and 31 December 2018. Primary outcome was diagnosis of future oesophageal and proximal gastric cancers. A time to event with competing risk analysis was performed, evaluating patient factors and whether the patient received H pylori treatment. Secondary analysis of those treated evaluated whether confirmed eradication was associated with cancer.
The cumulative incidence of oesophageal and proximal gastric cancers 5, 10 and 15 years after H pylori detection was 0.145%, 0.26% and 0.34%. Risk of future oesophageal or proximal gastric cancer was similar amongst whites (reference), African Americans (SHR 0.87, 95%CI 0.57-1.43) and American Indians (SHR 1.31, 95%CI 0.18-9.60) but substantially reduced in those of Asian (no cases amongst 213 H pylori positive) or native Hawaiian origin (no cases amongst 295 H pylori positive) (P < .001). Increasing age (SHR 1.17 per 5 years, 95% CI: 1.09-1.25, P < 0.001) and smoking (SHR 2.06, 95% CI: 1.33-3.18, P = 0.001) were associated with oesophageal and proximal gastric cancers. Neither treatment of H pylori nor eradication status were associated with cancer (P > 0.20).
In the largest study of US patients with H pylori, we demonstrate that rates of oesophageal and proximal gastric cancers after treatment of H pylori are low. Older age, and smoking are associated with future cancer, whilst Asian or Native Hawaiian race are protective. H pylori treatment and eradication are not associated with future cancer.
幽门螺杆菌感染是非近端胃癌最重要的危险因素,但也有观点认为它对食管腺癌和近端胃癌具有保护作用。
利用北美最大的已确诊幽门螺杆菌感染患者队列,评估未来食管和近端胃癌的发病率及危险因素。同时确定幽门螺杆菌的治疗和根除是否会改变未来食管和近端胃癌的风险。
对1994年1月1日至2018年12月31日期间退伍军人管理局的36803例确诊幽门螺杆菌感染患者(中位年龄60.4岁;91.8%为男性)进行回顾性队列研究。主要结局是未来食管和近端胃癌的诊断。进行了带有竞争风险分析的事件发生时间分析,评估患者因素以及患者是否接受了幽门螺杆菌治疗。对接受治疗的患者进行二次分析,评估确诊根除是否与癌症相关。
幽门螺杆菌检测后5年、10年和15年食管和近端胃癌的累积发病率分别为0.145%、0.26%和0.34%。白人(参照组)、非裔美国人(标准化风险比0.87,95%置信区间0.57 - 1.43)和美国印第安人(标准化风险比1.31,95%置信区间0.18 - 9.60)未来发生食管或近端胃癌的风险相似,但亚洲人(213例幽门螺杆菌阳性患者中无病例)或夏威夷原住民(295例幽门螺杆菌阳性患者中无病例)的风险大幅降低(P <.001)。年龄增加(每5年标准化风险比1.17,95%置信区间:1.09 - 1.25,P < 0.001)和吸烟(标准化风险比2.06,95%置信区间:1.33 - 3.18,P = 0.001)与食管和近端胃癌相关。幽门螺杆菌治疗及根除状态均与癌症无关(P > 0.20)。
在对美国幽门螺杆菌感染患者进行的最大规模研究中,我们证明幽门螺杆菌治疗后食管和近端胃癌的发病率较低。年龄较大和吸烟与未来患癌相关,而亚洲或夏威夷原住民种族具有保护作用。幽门螺杆菌治疗和根除与未来癌症无关。